Via $3.2B Morphic deal, Lilly gets oral integrin to compete in Entyvio’s class

Lilly’s takeout of Morphic gives it an oral integrin program that complements its recently approved IBD drug with a different mechanism, and could compete directly with an established, injectable blockbuster in its own class.

The $3.2 billion deal for nine-year-old Morphic Holding Inc. (NASDAQ:MORF) gives Eli Lilly and Co. (NYSE:LLY) MORF-057, a molecule targeting integrin α4β7 that is in two Phase II trials to treat ulcerative colitis and one Phase II study for Crohn’s disease...